Ultime notizie per Biprogy (OTC:NTULF) Azioni

Biprogy Inc is engaged in the service business such as cloud and outsourcing, sales/rental of computer systems and network systems, software development/sales and various system services.

NIHON UNISYS LTD ORD by Nihon Unisys, Ltd.

Biprogy Inc

WIIM

TUYA

Tuya shares are trading higher after the company announced an anchor investment by 65 Equity Partners.

Citigroup analyst Jonathan Woo initiates coverage on Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) with a Buy rating and announces Price Target of $65.

News

Price Target

Initiation

Analyst Ratings

AKRO

Citigroup Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $65

B of A Securities analyst Ruplu Bhattacharya initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $30.

INGM

B of A Securities Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $30

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) with a Buy and maintains $20 price target.

Reiteration

APRE

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

Citigroup analyst Atif Malik initiates coverage on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy rating and announces Price Target of $120.

ALAB

Citigroup Initiates Coverage On Astera Labs with Buy Rating, Announces Price Target of $120

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

BMO Capital analyst Jeffrey Silber upgrades Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from Market Perform to Outperform and lowers the price target from $137 to $125.

Upgrades

BFAM

BMO Capital Upgrades Bright Horizons Family to Outperform, Lowers Price Target to $125

Baird analyst Joe Vruwink maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and raises the price target from $305 to $330.

ADSK

Baird Maintains Outperform on Autodesk, Raises Price Target to $330

ARWR

Arrowhead Pharmaceuticals Submits New Drug Application To The US FDA For Plozasiran In Treatment Of Familial Chylomicronemia Syndrome

Loop Capital analyst Gary Mobley upgrades Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) from Hold to Buy and maintains the price target from $660 to $660.

MPWR

Loop Capital Upgrades Monolithic Power Systems to Buy, Maintains Price Target to $660

TWST

Twist Bioscience shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

CVS Health shares are trading higher after the company announced the addition of four new directors to its board.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and maintains $32 price target.

KURA

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

BIIB

Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.

MARA

Marathon Digital Holdings shares are trading lower after the company announced a $700 million convertible note offering to boost Bitcoin holdings and repurchase debt.

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.

QGEN

SYRS

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $154 to $162.

JAZZ

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162

Warner Bros. Discovery shares are trading higher after a WSJ report indicating that the company resolved a TV rights legal dispute with the NBA.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) with a Buy and maintains $50 price target.

HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target

Barclays analyst Nicholas Campanella downgrades Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) from Overweight to Equal-Weight and lowers the price target from $93 to $91.

Comments

Biprogy

Notizie

Ultime notizie per Biprogy (OTC:NTULF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO